EUS-Choledochoduodenostomy versus Hepaticogastrostomy combined with EUS-Gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): a prospective comparative study
Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S74
DOI: 10.1055/s-0044-1782847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von G. Vanella und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Combined Biliary (BO) and Gastric Outlet Obstruction (GOO) represent a challenging clinical scenario. Previous retrospective experiences have demonstrated higher risk of Dysfunction-Free survival (DFS) of EUS-guided Choledochoduodenostomy (EUS-CDS) versus EUS-Hepaticogastrostomy (EUS-HGS) in this scenario, but no prospective evidence is available.
Methods
All consecutive patients treated for double obstruction between 2021-2023 were eligible for inclusion upon receiving EUS-guided Gastroenterostomy (EUS-GE) for GOO and either EUS-CDS or EUS-HGS for BO according to endoscopist preference. DFS prospective surveillance started from the day the 2 procedures coexisted. Efficacy and safety were evaluated, with biliary dysfunctions as primary outcome and DFS using Kaplan-Meier estimates (with log-rank test) as primary measure.
Results
Twenty patients (75% with pancreatic cancer, 50% with metastatic disease) with EUS-GE were included (7 EUS-CDS and 13 EUS-HGS). No significant difference was detected at baseline. Technical success was 100% in both groups. EUS-CDS versus EUS-HGS showed similar clinical success (100% vs. 92.3%, p=0.5), a higher rate of post-procedural adverse events (42.9% vs. 7.7%, p=0.067, mostly related to severe/fatal cholangitis in the EUS-CDS group) and a higher rate of biliary dysfunctions during follow-up (57.1% vs. 16.7%, p=0.074). DFS was significantly shorter in the EUS-CDS group (39 [12-66] vs. 267 [192-344] days, p=0.0043), with a 30-days probability of DFS of 53.6% vs. 100%, HR=7.4 [1.1-52.3].
Conclusions
In this prospective comparison of patients with malignant double obstruction undergoing EUS-GE, treating jaundice with EUS-CDS versus EUS-HGS resulted in reduced probability of survival without biliary events, with detection of severe/fatal cholangitis. NCT04813055 Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Vanella, G., Leone, R., Dell'anna, G., Reni, M., Aldrighetti, L., Falconi, M., Capurso, G., & Arcidiacono, P. (2024). EUS-Choledochoduodenostomy versus Hepaticogastrostomy combined with EUS-Gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): a prospective comparative study. Endoscopy, 56(S 02 S 02), S74. https://doi.org/10.1055/s-0044-1782847
Vancouver
Vanella G, Leone R, Dell'anna G, Reni M, Aldrighetti L, Falconi M, et al. EUS-Choledochoduodenostomy versus Hepaticogastrostomy combined with EUS-Gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): a prospective comparative study. Endoscopy. 2024;56(S 02 S 02):S74. doi:10.1055/s-0044-1782847
BibTeX
@article{Vanella2024,
author = {Vanella, G. and Leone, R. and Dell'anna, G. and Reni, M. and Aldrighetti, L. and Falconi, M. and Capurso, G. and Arcidiacono, P.},
title = {EUS-Choledochoduodenostomy versus Hepaticogastrostomy combined with EUS-Gastroenterostomy in malignant double obstruction (CABRIOLET_Pro): a prospective comparative study},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 02 S 02},
pages = {S74},
doi = {10.1055/s-0044-1782847}
}
EUVIMED